High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 69, Issue 3, 1998, Pages 248-252

  Macciò, Antonio ^a   Lai, Paola ^a   Santona, Maria Cristina ^a   Pagliara, Loredana ^a   Melis, Gian Benedetto ^a   Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

C reactive protein; Cytokines; Ovarian cancer; Soluble IL 2 receptor; T cell response

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; MONONUCLEAR CELL; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032103338     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4974     Document Type: Article

References (39)

1. Gorelik E, Herberman R B. Immunological Control of Tumor Metastases. Fundamental Aspects of the Cancer: Cancer Growth and Progression V.I. 1989;Kluwer Academic, Dordrecht. p. 134-143.
2. Herberman R B. Immune Surveillance Hypothesis: Updated Formulation and Possible Effector Mechanisms. Tada T. Progress in Immunology. 1983;1157-1167 Japan Academic, Tokyo.
3. Diamanstein T. Interleukin-2 and the Interleukin-2 Receptor Complex. Rees R C. Biology and Clinical Application of IL2. 1990;15-22 Oxford Univ Press, Oxford.
4. Waldmann T A. The interleukin-2 receptor. J Biol Chem. 266:1991;2681-2684.
5. Voss S D, Hank J A, Nobis C A, Fisch P, Sosman J A, Sondel P M. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother. 29:1989;261-269.
6. Rosenberg S A, Lotze M T, Muul L M, Chang A E, Avis F P, Leitman S, Linehan M, Robertson C N, Lee R E, Rubin J T, Seipp C A, Simpson C G, White D E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med. 316:1987;889-897.
7. Ricevuti G, Mazzone A, Pasotti D, Notario A. The cytokine network: Their role in physiopathology and therapeutic implications. Int J Immunopath Pharmacol. 5:1992;67-76.
8. Lazenby A W, Roth J A, Owen-Schaub L B, Grimm E A. IL-1 synergy with IL-2 in the generation of lymphokine-activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 4:1992;479-487.
9. Wu S, Rodabaugh K, Martinez-Maza O, Watson J M, Silberstein D S, Boyer C M, Peters W P, Weinberg J B, Berek J S, Bast R C Jr. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6 and tumor necrosis factor-α Am J Obstet Gynecol. 166:1992;997-1007.
10. Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona M C, Del Giacco G S. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res. 25:1995;135-141.
11. Strassmann G, Fong M, Kenney J S, Jacob C O. Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest. 89:1992;1681-1684.
12. McNamara M J, Alexander H R, Norton J A. Cytokines and their role in the pathophysiology of cancer cachexia. J Parenteral Enteral Nutr. 16:1992;50S-55S.
13. Dinarello C A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 311:1984;1413-1418.
14. Castell J V, Gomez-Lechon M J, David M, Fabra R, Trullenque R, Heinrich P C. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 12:1990;1179-1186.
15. Raynes J G, Cooper E H. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol. 36:1983;798-803.
16. De Mello J, Struthers L, Turner R, Cooper E H, Giles G R. Multivariate analyses as aid to the diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer. 48:1983;341-348.
17. Broom J, Heys S D, Whiting P H, Park K G, Strachan A, Rothnie I, Franks C R, Eremin O. Interleukin 2 therapy in cancer: Identification of responders. Br J Cancer. 66:1992;1185-1187.
18. Blay J Y, Negrier S, Philip T, Favrot M, Mercatello A. Pretreatment serum CRP and response to Interleukin 2. Br J Cancer. 69:1994;200-201.
19. Steffen M, Durken M, Pichlmeier U, von dem Busche C, Stockschlader M, Kruger W, Budde-Steffen C, Zander A. Serum interleukin-6 levels during bone marrow transplantation: Impact on transplant-related toxicity and engraftment. Bone Marrow Transplant. 18:1996;301-307.
20. Mantovani G, Macciò A, Esu S, Lai P, Ghiani M, Turnu E, Contu G, Volpe A, Del Giacco G S. Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients. Int J Oncol. 5:1994;1211-1217.
21. Mantovani G, Coiana A, Cossu F, Floris C, Proto E, Macciò A, Pisano G, Taglieri G, Puxeddu G, Del Giacco G S. Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non PHA-prestimulated cells in patients with cancer. Tumori. 72:1986;375-382.
22. Mantovani G, Macciò A, Esu S, Lai P, Santona M C, Massa E, Dessì D, Melis G B, Del Giacco G S. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 33:1997;602-607.
23. Moradi M M, Carson L F, Weinberg B, Haney A F, Twiggs L B, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6 and tumor necrosis factor alpha in patients with ovarian epithelial cancer. Cancer. 72:1993;2433-2440.
24. Watson J M, Sensin Tappar J L, Berek J, Martinez-Maza O. Constitutive production of interleukin-6 by ovarian cell lines and by primary ovarian tumor cultures. Cancer Res. 50:1990;6959-6965.
25. Plante M, Rubin S C, Wong G Y, Federici M G, Finstad C L, Gastl G A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 73:1994;1882-1888.
26. Mantovani G, Macciò A, Pisano M, Versace R, Lai P, Esu S, Massa E, Ghiani M, Dessì D, Melis G B, Del Giacco G S. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 71:1997;724-731.
27. Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell. 54:1988;141-142.
28. Sherry B A, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry S F, Lundholm K G, Moldawer L L. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 3:1989;1956-1962.
29. Berek J S, Chung C, Kaldi K, Watson J M, Knox R M, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 164:1991;1038-1043.
30. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 71:1995;354-356.
31. VanHeyningen T K, Collins H L, Russell D G. IL-6 produced by macrophages infected with mycobacterium species suppresses T cell responses. J Immunol. 158:1997;330-337.
32. Hirte H W, Clark D A, O'Connell G, Rusthoven J, Mazurka J. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol. 142:1992;207-216.
33. Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood. 70:1987;1530-1535.
34. Barton D P, Blanchard D K, Michelini-Norris B, Nicosia S V, Cavanagh D, Djeu J Y. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. Blood. 81:1993;424-429.
35. Huang Y P, Perrin L H, Miescher P A, Zubler R H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 141:1988;827-833.
36. Deehan D J, Heyes S D, Simpson W G, Broom J, Franks C, Eremin O. In vivo cytokine production and recombinant interleukin 2 immunotherapy: An insight into the possible mechanisms underlying clinical responses. Br J Cancer. 69:1994;1130-1135.
37. Vachino G, Gelfand J A, Atkins M B, Tamerius J D, Demchak P, Mier J W. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): Binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood. 78:1991;2505-2513.
38. Hamoudi W H, Baum L L. Anti-C-reactive protein inhibits the calcium-dependent stage of natural killer cell activation. J Immunol. 146:1991;2873-2878.
39. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 69:1994;911-913.